Church v. Biden

District Court, District of Columbia·Decided November 8, 2021·No. Civil Action No. 2021-2815·Published

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

STEVEN CHURCH, et al., Plaintiffs, v.

Civil Action No. 21-2815 (CKK)

JOSEPH R. BIDEN, in his official capacity as President of the United States, et al., Defendants.

MEMORANDUM OPINION

(November 8, 2021)

The plaintiffs in this case include eighteen federal civilian employees 1 and two active-duty Marines 2 (collectively, “Plaintiffs”). By virtue of their federal civilian and military employment, Plaintiffs are subject to the recent COVID-19 vaccine mandates imposed under President Joseph R. Biden’s Executive Order 14043 and Secretary of Defense Lloyd Austin’s August 24, 2021 order for the vaccination of military personnel. Plaintiffs now challenge these vaccine mandates on constitutional and statutory grounds and request emergency injunctive relief preventing their enforcement.

Plaintiffs’ “extraordinary” request for immediate injunctive relief is not merited. At this early stage of the proceedings, the record reflects that each Plaintiff has requested an exemption to the very COVID-19 vaccine mandates they challenge. These exemption requests all remain pending, and during their pendency, no Plaintiff faces disciplinary action for refusing the COVID-19 vaccine. Plaintiffs, therefore, come before this Court complaining of a compulsory inoculation they may never need to take, and of adverse employment actions they may never

1 The “Federal Employee Plaintiffs” are: Steven Church, Lesley Church, Alma Gonzalez, Dynika Barnwell, Douglas Czerwinski, Jason Coffey, Joshua Schmidt, Melina Royer, Tamika Walls, Jaime Espitia, Somer Stephens, Alex Berne, Alan Camp, Stephanie Perrotta, Christopher Axtell, Grace Brown, Kristofor Hallfrisch, and Dorothy Morgan. 2 The “Service Member Plaintiffs” are: First Lieutenant Andrew Soto and Corporal Christopher Hall.

experience. This uncertainty weighs decisively against the ripeness of Plaintiffs’ claims and the irreparability of their purported injuries. Emergency injunctive relief is not appropriate under these circumstances. Accordingly, upon consideration of the pleadings, the relevant legal authorities, and the record as a whole, 3 the Court DENIES Plaintiffs’ [5] Emergency Application for a Temporary Restraining Order and Motion for Preliminary Injunction.

I. BACKGROUND

A. COVID-19 Pandemic & Vaccine Development Coronavirus disease (“COVID-19”) is an infectious disease caused by the SARS-CoV-2 virus. 4 Spread principally by “exposure to respiratory fluids,” the “initial presentation of a [COVID-19] infection ranges from no symptoms at all (asymptomatic) to severe illness and death; and even after recovery, various long-term health problems may linger.” Klaasen v. Trustees of Ind. Univ., --- F. Supp. 3d ---, 2021 WL 3073926, at *2 (N.D. Ind. July 18, 2021) (internal citations omitted); see Defs.’ Opp’n Ex. 9, Decl. of Colonel Tonya Rans (“Rans Decl.”) ¶ 7, ECF No. 13-9. 5 Because the virus causing COVID-19 can “be easily transmitted to others prior to symptom

3 This Memorandum Opinion focuses on the following documents:

x Verified Complaint for Declaratory and Injunctive Relief (“Compl.”), ECF No. 1;

x Plaintiffs’ Memorandum of Law in Support of Plaintiffs’ Emergency Application for Temporary Restraining Order and Preliminary Injunction (“Pls.’ Mot.”), ECF No. 5-1;

x Defendants’ Opposition to Emergency Application for Temporary Restraining Order and Preliminary Injunction (“Defs.’ Opp’n”), ECF No. 13; and x Plaintiffs’ Memorandum of Law in Reply to Defendants’ Opposition to Plaintiffs’ Application for Temporary Restraining Order and Preliminary Injunction (“Pls.’ Reply”), ECF No. 14.

In an exercise of its discretion, the Court finds that holding oral argument in this action would not be of assistance in rendering a decision. See LCvR 7(f). 4 World Health Org., Coronavirus disease (COVID-19), https://www.who.int/health-topics/ coronavirus#tab=tab_1 (last visited Nov. 8, 2021). 5 See also CDC, Scientific Brief: SARS-CoV2 Transmission, https://www.cdc.gov/coronavirus/2019- ncov/science/science-briefs/sars-cov-2-transmission.html (last visited Nov. 8, 2021); CDC, People with Certain Medical Conditions, https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/peoplewith -medical-conditions.html (last visited Nov. 8, 2021); Neal M. Dixit et al., Post-Acute COVID-19 Syndrome and the Cardiovascular System: What is Known?, 5 Am. Heart. J. Plus. 100025 (May 2021), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223036/.

development,” it can “infect significant numbers before being identified.” Rans Decl. ¶ 9. In recent months, a mutation of the SARS-CoV-2 virus known as the “Delta” variant has become the dominant strain of the virus; it is twice as contagious as previous variants. Id. ¶ 5. 6 To date, approximately 46 million cases of COVID-19 have been reported in the United States; the disease has claimed the lives of more than 751,000 Americans. 7 As another federal district court summarized, “COVID-19 caught the world unaware.

Initially, there were no vaccines or treatments[.]” Klaassen, 2021 WL 3073926, at *8. Shortly after then-President Donald J. Trump declared a national emergency on March 13, 2020, see 85 Fed. Reg. 15,337 (Mar. 13, 2020), the Secretary of the U.S. Department of Health and Human Services (“HHS”) determined that “circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic,” see 85 Fed. Reg. 18,250, 18,250–51 (Apr. 1, 2020). In such circumstances, the U.S. Food and Drug Administration (“FDA”) may issue an “emergency use authorization” (“EUA”) for FDA-regulated products “intended for use” in responding to the emergency, before such products receive FDA “approval.” See 21 U.S.C. § 360bbb-3(a)(1). In October 2020, the FDA issued guidance to vaccine developers, “outlining [the FDA’s] expectations for vaccine sponsors,” including the “scientific data and information” that would be required to obtain an EUA. 8

6 See also CDC, What We Know About the Science (Aug. 26, 2021), https://www.cdc.gov/coronavirus/ 2019-ncov/variants/delta-variant.html. 7 See CDC, COVID-19 Data Tracker, https://covid.cdc.gov/covid-data-tracker/#cases_casesper 100klast7days (last visited Nov. 8, 2021). 8 See FDA, Coronavirus (COVID-19) CBER-Regulated Biologics, Emergency Use Authorization, https://www.fda.gov/vaccines-blood-biologics/industry-biologics/coronavirus-covid-19-cber-regulatedbiologics (last visited Nov. 8, 2021). The latest version of the FDA’s Industry Guidance was issued on May 25, 2021, superseding the original guidance issued in October 2020 and a second iteration dated February 22, 2021. See Emergency Use Authorization for Vaccines to Prevent COVID-19, Guidance for Industry (May 25, 2021), https://www.fda.gov/media/142749/download.

Free access — add to your briefcase to read the full text and ask questions with AI

Church v. Biden, (D.D.C. 2021).

Church v. Biden (Church v. Biden) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Orloff v. Willoughby
345 U.S. 83 (Supreme Court, 1953)
Abbott Laboratories v. Gardner
387 U.S. 136 (Supreme Court, 1967)
Sampson v. Murray
415 U.S. 61 (Supreme Court, 1974)
Elrod v. Burns
427 U.S. 347 (Supreme Court, 1976)
Chappell v. Wallace
462 U.S. 296 (Supreme Court, 1983)
Texas v. United States
523 U.S. 296 (Supreme Court, 1998)
Sprint Corp. v. Federal Communications Commission
331 F.3d 952 (D.C. Circuit, 2003)
Hidalgo v. Federal Bureau of Investigation
344 F.3d 1256 (D.C. Circuit, 2003)
Chaplaincy of Full Gospel Churches v. England
454 F.3d 290 (D.C. Circuit, 2006)
Davis v. Pension Benefit Guaranty Corp.
571 F.3d 1288 (D.C. Circuit, 2009)
Mills v. District of Columbia
571 F.3d 1304 (D.C. Circuit, 2009)
Gordon v. Holder
632 F.3d 722 (D.C. Circuit, 2011)
Sherley v. Sebelius
644 F.3d 388 (D.C. Circuit, 2011)